STOCK TITAN

Akebia Therapeut - AKBA STOCK NEWS

Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.

Overview

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to transforming lives by developing innovative therapies for patients affected by kidney disease. Specializing in chronic kidney disease and anemia treatment, Akebia leverages its deep expertise in hypoxia‐inducible factor (HIF) biology to create novel oral therapeutics that address unmet medical needs in renal care.

Core Business and Product Portfolio

At its core, Akebia Therapeutics focuses on the research, development, and commercialization of therapies aimed at improving outcomes for patients with kidney disease. The company’s diversified portfolio includes:

  • Auryxia (ferric citrate): A treatment approved and marketed in the United States for the control of serum phosphorus levels in dialysis-dependent patients and the treatment of iron deficiency anemia in non-dialysis patients with chronic kidney disease. This product underscores the company’s expertise in addressing mineral and iron imbalances in renal disease.
  • Vafseo (vadadustat): An investigational, once-daily oral HIF prolyl hydroxylase inhibitor. Vafseo is designed to mimic the body’s natural response to hypoxia, thereby stimulating the endogenous production of erythropoietin and effectively managing anemia in chronic kidney disease patients on dialysis. Approved in select territories and under extensive phase 3 clinical evaluation, Vafseo is positioned as a potential new oral therapeutic option for anemia treatment.
  • Preclinical HIF-PH Inhibitor Programs: Akebia is also advancing a pipeline of next-generation HIF inhibitors aimed at further expanding its therapeutic reach in kidney disease and related conditions.

Market Position and Strategic Collaborations

Akebia Therapeutics occupies a distinctive niche within the biopharmaceutical sector, combining innovative science with robust commercial capabilities. The company is actively engaged in multiple strategic initiatives:

  • Commercial Launch Initiatives: With a strong emphasis on enabling widespread access to its therapies, particularly Vafseo, Akebia is executing comprehensive launch strategies. The company’s commercial team collaborates closely with dialysis organizations and renal care providers to secure contracting agreements and ensure market penetration.
  • Regulatory Milestones: The company has achieved significant regulatory approvals in various regions. Notably, Vafseo has been approved in select markets and is under active review in others. These accomplishments demonstrate the regulatory robustness and clinical promise of its product portfolio.
  • Bidirectional Collaborations: Akebia’s collaborations with key industry partners, including large dialysis organizations and research institutions, reflect its commitment to building a sustainable ecosystem in renal care. These efforts enhance the company’s ability to drive prescriber demand and improve patient outcomes through scientific exchange and clinical evidence generation.

Clinical Evidence and Research Commitment

Central to Akebia Therapeutics’ strategy is its investment in clinical research. The company has conducted extensive phase 3 clinical trials to evaluate the safety and efficacy of its lead product candidates. Data emerging from studies such as the INNO2VATE and VOICE trials have fortified the company’s scientific foundation, demonstrating the potential of its HIF-PH inhibitor to effectively manage anemia. Akebia continues to engage the nephrology community through the dissemination of clinical data at major scientific conferences and via peer-reviewed publications, thereby reinforcing its commitment to evidence-based medicine.

Operational Excellence and Financial Stability

Akebia’s business model is underpinned by operational excellence and a strong financial foundation. The company’s strategic initiatives are carefully designed to support long-term operational stability, including robust cash management and targeted expense control. By leveraging innovative financing strategies and maintaining diversified revenue streams from its approved product, the company is well-positioned to fund its ongoing clinical development and commercial launch activities without relying on speculative financial performance metrics.

Expertise, Experience, and Trustworthiness

With a team of seasoned professionals in the fields of biotechnology, clinical research, and commercial operations, Akebia Therapeutics exemplifies the principles of Experience, Expertise, Authoritativeness, and Trustworthiness (E-E-A-T). The company’s leadership has a proven track record in navigating complex regulatory landscapes, executing clinical trials, and forging strategic partnerships. This collective expertise, combined with transparent communication and rigorous adherence to clinical standards, underscores Akebia’s commitment to delivering high-quality therapeutics in the kidney disease space.

Industry Impact and Future Endeavors

Although Akebia remains focused on its current portfolio, its impact on the biopharmaceutical landscape is significant. By providing innovative treatment options for chronic kidney disease and anemia, the company not only addresses immediate patient needs but also paves the way for future advancements in renal therapeutics. The integration of cutting-edge research with practical, market-oriented strategies has established Akebia as a trusted entity among healthcare providers, regulatory authorities, and patients alike.

Conclusion

Akebia Therapeutics is redefining the management of kidney disease through its innovative approach to anemia treatment and its strategic focus on HIF biology. Its comprehensive portfolio, deep industry expertise, and commitment to clinical excellence make it a key player in the evolution of renal care. By continuously investing in robust scientific research and fostering strategic collaborations, Akebia is setting new benchmarks in the development and commercialization of effective, patient-centric therapies.

Rhea-AI Summary

Akebia Therapeutics® (Nasdaq: AKBA) reported Q1 2021 financial results, showing total revenue of $52.3 million, a decline from $88.5 million in Q1 2020. Collaboration revenue fell to $21.9 million from $59.3 million last year, while net product revenue increased by 4% to $30.4 million. The net loss widened to $69.6 million from $60.7 million. Notably, the NDA for vadadustat was submitted to the FDA, a key milestone for the company. Cash reserves remain strong at $272.8 million, expected to fund operations beyond the anticipated U.S. launch of vadadustat.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.05%
Tags
-
Rhea-AI Summary

On May 4, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to 9 new employees. A total of 197,200 shares were offered, each with an exercise price of $3.19, equal to the stock's closing price on April 30, 2021. The options will vest over four years, with 25% vesting on the first anniversary, and the remainder vesting quarterly. These grants comply with Nasdaq Listing Rule 5635(c)(4), intended to incentivize new hires.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
none
-
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced the publication of its Phase 3 clinical program results for vadadustat in the New England Journal of Medicine. The program evaluated vadadustat's effectiveness in treating anemia due to chronic kidney disease (CKD) in patients on and not on dialysis. A New Drug Application (NDA) was submitted to the FDA for vadadustat recently. The program demonstrated that vadadustat is noninferior to darbepoetin alfa for cardiovascular safety in dialysis patients, but did not meet the same for non-dialysis patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
Rhea-AI Summary

Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its financial results for Q1 2021 on May 10, 2021, prior to market opening. The results will be followed by a conference call at 9:00 a.m. ET to discuss financial outcomes and business highlights. Interested parties can join the call by dialing specific numbers or through a live webcast available on the company's website.

The replay will be accessible until May 16, 2021. Founded in 2007 and based in Cambridge, MA, Akebia focuses on developing therapeutics for kidney disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences earnings
-
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced that CEO John P. Butler will present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 1:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page, with a replay accessible for 30 days post-conference. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia aims to improve the lives of those affected by kidney disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences
-
Rhea-AI Summary

On April 2, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to 19 new employees totaling 131,000 shares to enhance recruitment efforts. These options have an exercise price of $3.38, the same as the stock's closing price on the grant date. Each option vests over four years, with 25% vesting after one year and the remainder quarterly, contingent on continued employment. The options adhere to Nasdaq Listing Rule 5635(c)(4) as part of the company's Inducement Award Program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced the submission of a New Drug Application (NDA) for vadadustat, aimed at treating anemia due to chronic kidney disease (CKD) in adult patients, both on and off dialysis. The NDA encompasses data from over 8,000 patients across 36 clinical trials. The FDA has a 60-day window to assess if the NDA is acceptable for review. Further, Akebia is collaborating with Otsuka Pharmaceutical for a Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
-
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the virtual National Kidney Foundation 2021 Spring Clinical Meetings from April 6-10, 2021. The company will present new data including a poster on a Phase 1 study regarding the drug vadadustat, an investigational treatment for anemia due to chronic kidney disease (CKD). Vadadustat's global Phase 3 program is complete, although it is only approved in Japan. Akebia will also support an educational session on CKD-related anemia treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced that its partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for Riona® Tablets (ferric citrate hydrate) to treat iron deficiency anemia (IDA) in adult patients in Japan. This approval follows the original marketing authorization obtained in 2014 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. Akebia's Auryxia® has similar indications in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
none

FAQ

What is the current stock price of Akebia Therapeut (AKBA)?

The current stock price of Akebia Therapeut (AKBA) is $1.88 as of April 3, 2025.

What is the market cap of Akebia Therapeut (AKBA)?

The market cap of Akebia Therapeut (AKBA) is approximately 410.2M.

What is the core focus of Akebia Therapeutics?

Akebia Therapeutics focuses on developing and commercializing innovative therapies for kidney disease, particularly treatments for anemia associated with chronic kidney disease using HIF biology.

Which products are part of Akebia's portfolio?

The company’s portfolio includes Auryxia (ferric citrate) for controlling serum phosphorus and treating iron deficiency anemia, and Vafseo (vadadustat), an oral HIF prolyl hydroxylase inhibitor for managing anemia in dialysis patients.

How does Vafseo work as a treatment?

Vafseo is designed as a once-daily oral tablet that activates the body’s natural response to hypoxia, thereby stimulating endogenous erythropoietin production to help manage anemia in patients with kidney disease on dialysis.

What distinguishes Akebia Therapeutics in the biopharmaceutical industry?

Akebia is distinguished by its integrated approach that combines rigorous clinical research, strong regulatory achievements, strategic collaborations with dialysis organizations, and a commitment to evidence-based innovation in renal care.

How does Akebia support its commercial launch strategies?

The company executes comprehensive launch strategies by partnering with major dialysis providers and securing contracting agreements, ensuring broad market access for its products and facilitating effective prescriber engagement.

What type of clinical research does Akebia undertake?

Akebia conducts extensive phase 3 clinical trials, including studies such as INNO2VATE and VOICE, to evaluate the safety and efficacy of its lead candidates like Vafseo, and regularly publishes findings at major scientific conferences.

What role does regulatory approval play in Akebia’s operations?

Regulatory approvals are central to Akebia’s business model, as they validate the safety and efficacy of its therapies. The company has secured approvals for Auryxia and is actively engaging with regulatory bodies for Vafseo across various markets.

How does Akebia demonstrate E-E-A-T in its business practices?

Akebia demonstrates E-E-A-T by maintaining a team of seasoned experts, investing in high-quality clinical research, achieving regulatory milestones, and fostering transparent, evidence-based communication with healthcare professionals and regulators.
Akebia Therapeut

Nasdaq:AKBA

AKBA Rankings

AKBA Stock Data

410.18M
232.73M
4.45%
28.9%
6.82%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CAMBRIDGE